Leukemia Research
Volume 30, Issue 2 , Pages 170-177 , February 2006

Allelic expression and quantitative RT-PCR study of TAp73 and ΔNp73 in non-Hodgkin's lymphomas

  • Marta Cuadros

      Affiliations

    • Human Genetics Department, Spanish National Cancer Centre (CNIO), Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 91 224 69 49; fax: +34 91 224 69 23.
    • ,
  • Gloria Ribas

      Affiliations

    • Human Genetics Department, Spanish National Cancer Centre (CNIO), Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    • ,
  • Victoria Fernández

      Affiliations

    • Human Genetics Department, Spanish National Cancer Centre (CNIO), Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    • ,
  • Carmen Rivas

      Affiliations

    • Pathology Department, Jiménez Díaz Foundation Hospital, Reyes Católicos s/n, 28040 Madrid, Spain
    • ,
  • Javier Benitez

      Affiliations

    • Human Genetics Department, Spanish National Cancer Centre (CNIO), Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    • ,
  • Beatriz Martinez-Delgado

      Affiliations

    • Human Genetics Department, Spanish National Cancer Centre (CNIO), Melchor Fernandez Almagro 3, 28029 Madrid, Spain

Received 4 March 2005 ,Revised 30 June 2005 ,Accepted 30 June 2005.

References 

  1. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90(4):809–819
  2. Melino G, De Laurenzi V, Vousden KH. p73: friend or foe in tumorigenesis. Nat Rev Cancer. 2002;2(8):605–615
  3. Sozzi G, Bertoglio MG, Pilotti S, Rilke F, Pierotti MA, Della Porta G. Cytogenetic studies in primary and metastatic neuroendocrine Merkel cell carcinoma. Cancer Genet Cytogenet. 1988;30(1):151–158
  4. Martinsson T, Weith A, Cziepluch C, Schwab M. Chromosome 1 deletions in human neuroblastomas: generation and fine mapping of microclones from the distal 1p region. Genes Chromosomes Cancer. 1989;1(1):67–78
  5. Devilee P, van Vliet M, Bardoel A, Kievits T, Kuipers-Dijkshoorn N, Pearson PL, et al. Frequent somatic imbalance of marker alleles for chromosome 1 in human primary breast carcinoma. Cancer Res. 1991;51(3):1020–1025
  6. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol. 1997;56(10):1098–1104
  7. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med. 1998;188(9):1763–1768
  8. Jost CA, Marin MC, Kaelin WG. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature. 1997;389(6647):191–194
  9. Ahomadegbe JC, Tourpin S, Kaghad M, Zelek L, Vayssade M, Mathieu MC, et al. Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers. Oncogene. 2000;19(47):5413–5418
  10. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2(3):305–316
  11. Tokuchi Y, Hashimoto T, Kobayashi Y, Hayashi M, Nishida K, Hayashi S, et al. The expression of p73 is increased in lung cancer, independent of p53 gene alteration. Br J Cancer. 1999;80(10):1623–1629
  12. Douc-Rasy S, Barrois M, Echeynne M, Kaghad M, Blanc E, Raguenez G, et al. DeltaN-p73alpha accumulates in human neuroblastic tumors. Am J Pathol. 2002;160(2):631–639
  13. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med. 2002;196(6):765–780
  14. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, et al. Transactivation-deficient p73alpha (p73Delta exon2) inhibits apoptosis and competes with p53. Oncogene. 2001;20(4):514–522
  15. Putzer BM, Tuve S, Tannapfel A, Stiewe T. Increased DeltaN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promoter-derived DeltaN’-p73 transcript. Cell Death Differ. 2003;10(5):612–614
  16. Mai M, Qian C, Yokomizo A, Tindall DJ, Bostwick D, Polychronakos C, et al. Loss of imprinting and allele switching of p73 in renal cell carcinoma. Oncogene. 1998;17(13):1739–1741
  17. Mai M, Yokomizo A, Qian C, Yang P, Tindall DJ, Smith DI, et al. Activation of p73 silent allele in lung cancer. Cancer Res. 1998;58(11):2347–2349
  18. Martinez-Delgado B, Melendez B, Cuadros M, Jose Garcia M, Nomdedeu J, Rivas C, et al. Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas. Int J Cancer. 2002;102(1):15–19
  19. Chi SG, Chang SG, Lee SJ, Lee CH, Kim JI, Park JH. Elevated and biallelic expression of p73 is associated withprogression of human bladder cancer. Cancer Res. 1999;59(12):2791–2793
  20. Takahashi H, Ichimiya S, Nimura Y, Watanabe M, Furusato M, Wakui S, et al. allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res. 1998;58(10):2076–2077
  21. Yokomizo A, Mai M, Tindall DJ, Cheng L, Bostwick DG, Naito S, et al. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene. 1999;18(8):1629–1633
  22. Melino G, Vitale L, Abetti P, Bossi A, Fabbri T, Saracino V, et al. Clinical investigation of hyaluronidase and nerve growth factor (NGF) at the ocular level: detailed review of the international literature. Clin Ter. 2002;153(2):119–126
  23. Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer BM. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res. 2002;62(13):3598–3602
  24. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F, et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 2001;8(12):1213–1223
  25. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res. 2002;62(3):636–641
  26. Kartasheva NN, Contente A, Lenz-Stoppler C, Roth J, Dobbelstein M. p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene. 2002;21(31):4715–4727
  27. Stiewe T, Theseling CC, Putzer BM. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem. 2002;277(16):14177–14185
  28. Benard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Hum Mutat. 2003;21(3):182–191
  29. Waltermann A, Kartasheva NN, Dobbelstein M. Differential regulation of p63 and p73 expression. Oncogene. 2003;22(36):5686–5693
  30. Blint E, Phillips AC, Kozlov S, Stewart CL, Vousden KH. Induction of p57(KIP2) expression by p73beta. Proc Natl Acad Sci USA. 2002;99(6):3529–3534
  31. Zhu J, Jiang J, Zhou W, Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 1998;58(22):5061–5065
  32. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, et al. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 2002;9(3):246–251
  33. Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J, et al. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst. 1999;91(13):1154–1158
  34. Saez AI, Artiga MJ, Romero C, Rodriguez S, Cigudosa JC, Perez-Rosado A, et al. Development of a real-time reverse transcription polymerase chain reaction assay for c-myc expression that allows the identification of a subset of c-myc+ diffuse large B-cell lymphoma. Lab Invest. 2003;83(2):143–152
  35. Martinez-Delgado B, Robledo M, Arranz E, Infantes F, Echezarreta G, Marcos B, et al. Correlation between mutations in p53 gene and protein expression in human lymphomas. Am J Hematol. 1997;55(1):1–8
  36. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159(6):2249–2256
  37. Zwahlen D, Tschan MP, Grob TJ, Peters UR, Fink D, Haenggi W, et al. Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours. Int J Cancer. 2000;88(1):66–70
  38. Peters UR, Tschan MP, Kreuzer KA, Baskaynak G, Lass U, Tobler A, et al. Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis. Cancer Res. 1999;59(17):4233–4236
  39. Peters UR, Hasse U, Oppliger E, Tschan M, Ong ST, Rassool FV, et al. Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia. Oncogene. 1999;18(1):79–85
  40. Banelli B, Casciano I, Romani M. Methylation-independent silencing of the p73 gene in neuroblastoma. Oncogene. 2000;19(39):4553–4556
  41. Zaika AI, Kovalev S, Marchenko ND, Moll UM. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res. 1999;59(13):3257–3263
  42. Korabiowska M, Ruschenburg I, Betke H, Stachura J, Schlott T, Cardo CC, et al. Downregulation of the retinoblastoma gene expression in the progression of malignant melanoma. Pathobiology. 2001;69(5):274–280
  43. Tuve S, Wagner SN, Schittek B, Putzer BM. Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression. Int J Cancer. 2004;108(1):162–166
  44. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, et al. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res. 2004;64(7):2449–2460
  45. Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH, Putzer BM. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res. 2004;10(2):626–633

PII: S0145-2126(05)00275-4

doi: 10.1016/j.leukres.2005.06.024

Leukemia Research
Volume 30, Issue 2 , Pages 170-177 , February 2006

Article Tools

* Image Usage & Resolution